Angicyte® is the future blueprint for vascular cell therapy.

 

We have developed a robust, scalable protocol to generate a highly pure population of vascular cells from small volumes of blood.

 

This proprietary cell product is called Angicyte®. Compared to conventional endothelial cells, Angicyte® demonstrates superior performance across critical functional benchmarks, including stronger vessel formation, improved barrier integrity and a favourable metabolic profile suitable for functioning in tissues with deficient oxygen supply.

 

It is inherently more scalable for production and consistently demonstrates high functional performance.

 

Beyond ophthalmology, these attributes support other ex vivo therapeutic applications, including tissue engineering.